PRIMARY STUDY

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Key Findings:  Animal trials suggest that the effects of CBD depend on dose, strain, can vary in acute and chronic setting, and with different form of administration. CBD is posited to induce its effects via CB1, CB2, 5-HT1A receptor sites and neurogenesis factors. Early clinical trials support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and a positive risk-benefit profile.